Hyperfine, Inc. (HYPR)
NASDAQ: HYPR · IEX Real-Time Price · USD
1.205
-0.035 (-2.82%)
At close: Jul 19, 2024, 4:00 PM
1.220
+0.015 (1.24%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States.
The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services.
It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.
Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
Hyperfine, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Ms. Maria Sainz |
Contact Details
Address: 351 New Whitfield Street Guilford, Connecticut 06437 United States | |
| Phone | 866-796-6767 |
| Website | hyperfine.io |
Stock Details
| Ticker Symbol | HYPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833769 |
| CUSIP Number | 44916K106 |
| ISIN Number | US44916K1060 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Maria Sainz | Chief Executive Officer, President and Director |
| R. Scott Huennekens CPA, M.B.A. | Executive Chairman |
| Dr. Jonathan M. Rothberg Ph.D. | Founder and Vice Chairman |
| Brett Hale | Chief Administrative Officer, Chief Financial Officer, Chief Compliance Officer, Treasurer and Corporate Secretary |
| Dr. Thomas Teisseyre Ph.D. | Chief Operating Officer |
| Chip Truwit FACR, M.D. | Vice President of Scientific Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 22, 2024 | 424B5 | Filing |